Welcome to our dedicated page for Perrigo Co Plc news (Ticker: PRGO), a resource for investors and traders seeking the latest updates and insights on Perrigo Co Plc stock.
Perrigo Company plc (NYSE: PRGO) is a pure-play self-care and consumer health company whose news flow is closely tied to its over-the-counter (OTC) product portfolio, category performance and strategic initiatives. The company regularly issues updates on its Consumer Self-Care Americas and Consumer Self-Care International segments, highlighting trends in categories such as Upper Respiratory, Pain & Sleep Aids, Digestive Health, Nutrition, Vitamins, Minerals and Supplements, Women’s Health, Skin Care, Oral Care and Healthy Lifestyle.
On this page, readers can follow Perrigo’s earnings announcements, where the company discusses net sales, organic growth, segment performance and the impact of divestitures and exited products. These releases often reference store brand market share gains in OTC categories, performance of key brands and progress under its Three-S plan (Stabilize, Streamline, Strengthen). Updates on Project Energize, the global investment and efficiency program designed to support the One Perrigo growth strategy, are also a recurring theme in recent communications.
Perrigo’s news also covers portfolio actions and strategic reviews. The company has disclosed an agreement to sell its Dermacosmetics branded business in certain European markets and has announced strategic reviews of its Oral Care and infant formula businesses. In addition, readers will find announcements related to dividends, participation in investor conferences and brand-level initiatives, such as collaborations involving Opill®, which Perrigo describes as the first daily birth control pill available without a prescription in the United States.
Investors, analysts and consumers can use this news feed to monitor how Perrigo is positioning its OTC and self-care portfolio, how its store brand and branded businesses are performing across regions and categories, and how management is adjusting the company’s structure and investments in response to market conditions.
Perrigo (NYSE: PRGO), a leading provider of Consumer Self-Care Products, has announced it will release its first quarter 2025 financial results on Wednesday, May 7th, 2025. The company will host a conference call at 8:30 A.M. (EST).
Investors can access the earnings conference call via webcast through Perrigo's investor relations website or by phone. A taped replay will be available from approximately 12:00 P.M. (EST) on May 7 until midnight May 14, 2025.
Perrigo specializes in over-the-counter (OTC) health and wellness solutions, focusing on consumer self-managed preventive and treatment products.
Perrigo (NYSE: PRGO) unveiled its strategic 'Three-S' plan at its Virtual Investor Day, focusing on consumerizing, simplifying, and scaling its global self-care platform. The plan includes: Stabilizing Consumer Self-Care Americas store brand and infant formula businesses, Streamlining the global portfolio and operations, and Strengthening investments in key 'High-Grow' brands.
The company announced its fiscal year 2025 targets, including: 1-3% all-in net sales growth, 2.5-4.5% organic net sales growth, ~40% adjusted gross margin, and adjusted EPS of $2.90-$3.10 (13-21% growth). For fiscal years 2025-2027, Perrigo targets organic net sales CAGR of 2.5-4.5%, adjusted gross margin expansion of 200-400 basis points, and net leverage reduction to less than 3x adjusted EBITDA by 2027.
Perrigo (PRGO) reported Q4 2024 financial results with net sales of $1.14 billion, declining 1.6% year-over-year, while organic growth was 0.7%. The company delivered fiscal year 2024 adjusted EPS of $2.57, meeting guidance expectations, despite reporting a loss of $(1.17) per share.
Q4 highlights include 17% growth in infant formula sales and expansion of adjusted operating margin by 260 basis points to 17.0%. The Consumer Self-Care Americas (CSCA) segment reported flat sales at $744 million, while Consumer Self-Care International (CSCI) saw a 4.5% decline to $394 million.
The company's Project Energize initiative achieved gross annual savings of $139 million in 2024, with $17 million reinvested. The program is expected to deliver annualized pre-tax savings of $140-170 million by 2026. Notably, Perrigo's Wisconsin infant formula facility received a 'No Action Indicated' status from the FDA, marking significant improvement from its previous status.
Perrigo (NYSE: PRGO), a leading provider of Consumer Self-Care Products, has announced its participation in the UBS 2025 Global Consumer and Retail Conference. President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra will present on Wednesday, March 12 at 10 AM ET in New York City.
The presentation will be accessible via webcast on Perrigo's investor relations website. Perrigo specializes in over-the-counter (OTC) health and wellness solutions, focusing on empowering consumers with self-managed healthcare options.
The company has noted that their conference presentation will include forward-looking statements, subject to risks and uncertainties that may cause actual results to differ from current projections. Interested parties are encouraged to review Perrigo's SEC filings for detailed risk factors and business conditions.
Perrigo (NYSE: PRGO) has announced a 5% increase in its quarterly dividend to $0.290 per share, up from $0.276, equivalent to $1.16 annually. The dividend will be payable on March 25, 2025, to shareholders of record on March 7, 2025.
This marks Perrigo's 22nd consecutive year of dividend increases, demonstrating the company's commitment to shareholder returns. Perrigo is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions focused on empowering consumers in self-managed healthcare.
Opill®, the first over-the-counter birth control pill in the U.S., announced a major educational initiative including a multi-state college tour and expanded partnership with the WNBA. The initiative, called Level The Court, is developed in collaboration with the Black Women's Health Imperative (BWHI) to improve reproductive health education and access.
The college tour will visit 15 institutions, prioritizing states with restrictive reproductive health laws, including Texas, Tennessee, Indiana, and Arkansas. The University of South Carolina will host a WNBA event on February 25, 2025. The initiative includes the establishment of the BWHI Opill® Access Fund, providing three-month supplies to Black women facing challenges.
Stand-up comedian Hannah Berner joins the campaign to promote awareness about over-the-counter birth control options. The program targets nearly six million students in states with reproductive restrictions, featuring campus events, player appearances, and educational resources.
Perrigo (NYSE: PRGO) has announced it will release its fourth quarter and fiscal year 2024 financial results after U.S. market close on February 27, 2025. The company will follow this with a Virtual Investor Day on February 28, 2025, starting at 8:00 AM EST.
Interested participants can access the Virtual Investor Day event through Perrigo-Investor-Day-2025.open-exchange.net/welcome and are encouraged to register in advance. Perrigo is a leading provider of Consumer Self-Care Products and over-the-counter (OTC) health and wellness solutions focused on preventive and self-managed healthcare.
Perrigo (NYSE: PRGO) announced the expansion of its Chief Scientific Office, integrating global quality, pharmacovigilance, patient safety, regulatory affairs, and innovation teams to enhance organizational agility. Abbie Lennox has been appointed as Executive Vice President and Chief Scientific Officer, joining from Bayer where she served as Executive Board Member and Chief Trust and Science Officer.
Lennox brings experience in driving regulatory excellence and product innovation, having led multiple launches across various health categories and Rx-to-OTC switches. Notable achievements include leading the U.S. Rx-to-OTC switch for Astepro® and introducing Rennie® Gum in Europe.
The previous Chief Scientific Officer, Alison Ives, will transition to lead a newly formed Disruptive Growth Team, focusing on identifying emerging growth opportunities through category disruption and new market entry.
Perrigo (PRGO) reported Q3 2024 financial results with net sales of $1.1 billion, down 3.2% year-over-year. Despite revenue decline, the company showed operational improvements with adjusted operating income increasing 21.3% to $182 million and adjusted operating margin expanding 340 basis points to 16.8%. The infant formula business showed recovery with 3% growth year-over-year and 58% sequential growth. Adjusted EPS was $0.81, up 26.6% from $0.64 in the prior year. The company reaffirmed its fiscal 2024 adjusted EPS outlook of $2.50-$2.65 while expecting organic net sales growth to be at the lower end of its previously stated range of -3% to -1%.
Perrigo reported Q3 2024 financial results with net sales of $1.1 billion, declining 3.2% versus prior year. The company achieved meaningful operating income growth and margin expansion, with adjusted operating income increasing 21.3% to $182 million. Infant formula business showed significant recovery with 3% net sales growth year-over-year and 58% sequential growth.
Key highlights include:
- GAAP operating income of $80 million, up from $62 million
- Adjusted diluted EPS of $0.81, up 26.6% from $0.64
- Gross margin expanded 160 basis points to 41.0%
- Operating margin increased 340 basis points to 16.8%
The company reaffirmed its fiscal 2024 adjusted EPS outlook of $2.50 to $2.65, while expecting organic net sales growth towards the lower end of its previously stated range of -3% to -1%.